CRYSTALSFIRST

CrystalsFirst

@crystalsfirst

Hamburg, HH
https://www.crystalsfirst.com
Biotechnology Research

Overview

About CrystalsFirst

Small-molecule drug discovery is being compared to searching for a needle in a haystack. At CrystalsFirst, we have built a better way: using a “magnet” to attract the best-suited molecules.

MAGNET Discovery Engine accelerates small molecule drug discovery by uniting patented high-throughput structural biology with AI-powered design. This integration of vertically scaling proprietary “labware” with horizontally scaling of AI-driven design tools offers the industry to systematically uncover, validate, and optimize ligands with a speed and confidence that was previously out of reach.

With a track record of over 60 structurally-enabled drug targets, the MAGNET has been applied successfully across: target-to-hit discovery, hit-to-lead development, lead optimization.

Headquarters

Hamburg, HH

Website

https://www.crystalsfirst.com

Company Size

11-50 employees

Industry

Biotechnology Research

Company Type

Privately Held

Founded

2025

Specialties

drug discovery, lead discovery, hit finding, structural biology, fragment-based drug discovery, FBDD, FBLD, fragment-based lead discovery, crystallography, lead optimization, generative AI, machine learning, and virtual screening

Posts